Table 4.

The laboratory data of the patients in both naltrexone and placebo groups.

	Total		NLTX		Placebo		P
	Mean ± SD	Median (range)	Mean ± SD	Median (range)	Mean ± SD	Median (range)
WBC ×106  µL	11.5 ± 3.9	11.0 (34 to 21.7)	10.6 ± 34	10.1 (34 to 17)	12.3 ± 42	11.4 (65 to 2.17)	0.12†
RBC ×106  µL	4.62 ± 0.48	4.56 (3.87 to 5.9)	4.68 ± 0.49	4.62 (3.87 to 5.52)	4.56 ± 0.49	4.51 (3.91 to 5.9)	0.40†
Hb (mg/dL)	13.1 ± 2.6	13.4 (1.3 to 16.6)	13.7 ± 1.9	14.1 (9.1 to 16.2)	12.5 ± 3.1	12.4 (1.3 to 16.6)	0.10†
Hct (%)	40.4 ± 4.6	39 (30.1 to 49.8)	40.8 ± 5	40.3 (30.1 to 48.4)	40 ± 4.3	39 (34 to 49.8)	0.64‡
Platelet ×103  µL	225 ± 89	225 (46 to 599)	233 ± 100	232 (97 to 599)	217 ± 79	220 (46 to 396)	0.53†
Blood sugar (mg/dL)	117 ± 59	106 (50 to 317)	101 ± 41	91 (53 to 197)	133 ± 70	118 (50 to 317)	0.03‡
Blood urea (mg/dL)	27 ± 12	24 (15 to 69)	25 ± 8	24 (15 to 47)	29 ± 14	26 (15 to 69)	0.35‡
Creatinine (mg/dL)	1 ± 0.4	0.9 (0.6 to 3)	0.9 ± 0.2	0.9 (0.6 to 1.5)	1.1 ± 0.5	0.9 (0.6 to 3)	0.13‡
SGOT (U/L)	32 ± 37	22 (11 to 241)	22 ± 11	18 (12 to 63)	41 ± 49	25 (11 to 241)	0.04‡
SGPT (U/L)	28 ± 31	18 (5 to 167)	24 ± 22	16 (10 to 105)	32 ± 38	21 (5 to 167)	0.58‡
LDH (U/L)	519 ± 394	422 (216 to 2780)	526 ± 514	416 (290 to 2780)	514 ± 243	422 (216 to 1324)	0.26‡
CPK (U/L)	387 ± 914	110 (50 to 4450)	105 ± 37	99 (59 to 170)	656 ± 1231	144 (50 to 4450)	0.04†
ALP (U/L)	180 ± 61	175 (11 to 320)	177 ± 53	178 (98 to 310)	182 ± 69	172 (11 to 320)	0.80†
Na (mEq/L)	163 ± 169	139 (132 to 1346)	187 ± 241	139 (132 to 1346)	140 ± 3	140 (136 to 147)	0.73‡
K (mEq/L)	4 ± 0.4	4 (3.4 to 4.8)	4 ± 0.4	4 (3.4 to 4.6)	4.1 ± 0.4	4.1 (3.4 to 4.8)	0.17†
Bili. T (mg/dL)	0.6 ± 0.3	0.5 (0 to 1.4)	0.6 ± 0.3	0.5 (0 to 1.4)	0.6 ± 0.3	0.5 (0 to 1.4)	0.62‡
Bili. D (mg/dL)	0.2 ± 0.1	0.2 (0.1 to 1)	0.2 ± 0.2	0.2 (0.1 to 1)	0.2 ± 0.1	0.1 (0.1 to 0.3)	0.02‡

^†Based on Student's t-test. ^‡Based on Mann-Whitney U test.